Patents by Inventor Ioav Cabantchik

Ioav Cabantchik has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of Deferiprone and Methods to Treat and/or Prevent Friedreich Ataxia Resulting from Intracellular Mishandling of Iron
    Publication number: 20130190365
    Abstract: A therapeutically effective amount of deferiprone or deferasirox or physiologically acceptable salts thereof for the prevention, stabilization, treatment, or reversal of iron-induced FRDA disease in patients resulting from mitochondrial iron-induced damage to preferentially reduce the iron stores in the mitochondria. Also for the treatment of other conditions affecting the brain where a key element in the generation of the resultant pathology is the intracellular mishandling of iron.
    Type: Application
    Filed: January 31, 2013
    Publication date: July 25, 2013
    Inventors: Arnold Munnich, Michael Spino, Ioav Cabantchik
  • TREATMENT OF ENDOCRINE DYSFUNCTION USING IRON CHELATORS
    Publication number: 20100004303
    Abstract: The invention relates to the use of an iron chelator for the treatment or prevention of pathologies due to iron loading, e.g. related to a dysfunction, in particular a reduction or inhibition, of the secretory function of cells from endocrine glands, in the human or animal body.
    Type: Application
    Filed: August 3, 2007
    Publication date: January 7, 2010
    Applicant: NOVARTIS AG
    Inventors: Ioav Cabantchik, Hanspeter Nick
  • USE OF DEFERIPRONE AND METHODS TO TREAT AND/OR PREVENT FRIEDREICH ATAXIA RESULTING FROM INTRACELLULAR MISHANDLING OF IRON
    Publication number: 20090023784
    Abstract: A therapeutically effective amount of deferiprone or deferasirox or physiologically acceptable salts thereof for the prevention, stabilization, treatment, or reversal of iron-induced FRDA disease in patients resulting from mitochondrial iron-induced damage to preferentially reduce the iron stores in the mitochondria. Also for the treatment of other conditions affecting the brain where a key element in the generation of the resultant pathology is the intracellular mishandling of iron.
    Type: Application
    Filed: February 21, 2007
    Publication date: January 22, 2009
    Inventors: Arnold Munnich, Michael Spino, Ioav Cabantchik
  • Use of deferiprone and methods to treat and/or prevent Friedreich Ataxia resulting from intracellular mishandling of iron
    Publication number: 20070197649
    Abstract: A therapeutically effective amount of deferiprone or deferasirox or physiologically acceptable salts thereof for the prevention, stabilization, treatment, or reversal of iron-induced FRDA disease in patients resulting from mitochondrial iron-induced damage to preferentially reduce the iron stores in the mitochondria. Also for the treatment of other conditions affecting the brain where a key element in the generation of the resultant pathology is the intracellular mishandling of iron.
    Type: Application
    Filed: February 21, 2007
    Publication date: August 23, 2007
    Inventors: Arnold Munnich, Michael Spino, Ioav Cabantchik